Table 2. Associations between age-standardised incidence rate and DALY rate of autoimmune disease and varied country indexes in children and adolescents.
| Childhood (0–9 years) | Adolescence (10–24 years) | |||
| rASIR (95% CI) | rASDR (95% CI) | rASIR (95% CI) | rASDR (95% CI) | |
| N=171 | ||||
| ESG Index | ||||
| Diabetes mellitus type 1 | −0.61 (−0.70 to −0.51) | 0.66 (0.56 to 0.73) | −0.54 (−0.64 to −0.42) | 0.33 (0.19 to 0.46) |
| Rheumatoid arthritis | −0.62 (−0.71 to −0.52) | −0.29 (−0.42 to −0.14) | −0.57 (−0.67 to −0.46) | −0.64 (−0.72 to −0.54) |
| Inflammatory bowel disease | −0.45 (−0.57 to −0.33) | 0.26 (0.11 to 0.39) | −0.66 (−0.73 to −0.56) | −0.57 (−0.66 to −0.45) |
| Psoriasis | −0.62 (−0.71 to −0.52) | −0.62 (−0.70 to −0.51) | −0.65 (−0.73 to −0.55) | −0.65 (−0.73 to −0.55) |
| N=85 | ||||
| Healthcare index | ||||
| Diabetes mellitus type 1 | 0.37 (0.17 to 0.54) | −0.36 (−0.53 to −0.16) | 0.24 (0.03 to 0.43) | −0.34 (−0.51 to −0.13) |
| Rheumatoid arthritis | 0.34 (0.14 to 0.51) | 0.29 (0. 08 to 0.47) | 0.07 (−0.14 to 0.28) | 0.23 (0.02 to 0.42) |
| Inflammatory bowel disease | 0.24 (0.03 to 0.44) | −0.16 (−0.36 to 0.06) | 0.42 (0.23 to 0.58) | 0.33 (0.12 to 0.50) |
| Psoriasis | 0.36 (0.16 to 0.53) | 0.37 (0.17 to 0.54) | 0.33 (0.12 to 0.50) | 0.35 (0.14 to 0.52) |
| N=77 | ||||
| Quality of Life Index | ||||
| Diabetes mellitus type 1 | 0.64 (0.49 to 0.76) | −0.38 (−0.55 to −0.17) | 0.65 (0.50 to 0.77) | −0.14 (−0.35 to 0.08) |
| Rheumatoid arthritis | 0.53 (0.35 to 0.68) | 0.26 (0.03 to 0.45) | 0.24 (0.01 to 0.44) | 0.40 (0.20 to 0.57) |
| Inflammatory bowel disease | 0.37 (0.16 to 0.55) | −0.14 (−0.35 to 0.09) | 0.65 (0.49 to 0.76) | 0.57 (0.40 to 0.70) |
| Psoriasis | 0.59 (0.42 to 0.72) | 0.58 (0.41 to 0.71) | 0.60 (0.44 to 0.73) | 0.60 (0.44 to 0.73) |
ASDRage-standardised DALYs rateASIRage-standardised incidence rateDALYsdisability-adjusted life-yearsESGEnvironmental, Social and Governance Index